Memo Protein Is Prognostic Marker for Poor Outcome in Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

Since current advancements in breast cancer therapy have greatly reduced the death rate from primary breast tumors, patients are more likely to die from metastases. According to a study published in Science Signaling, the protein Memo is needed for cell migration and invasion. It acts as an excellent prognostic marker for poor patient outcome as well. Group leader Nancy Hynes and collaborators at the Friedrich Miescher Institute for Biomedical Research studied the structure and biochemistry of the protein, and they found that Memo binds copper and therefore influences the oxidative environment of a cell, which is significant because numerous proteins are activated through oxidation and stimulate cell movement. In addition, high concentrations of Memo correlated with several parameters of aggressive disease. This indication performed better than lymph node status, which is the current most important prognostic marker for disease-free survival of breast cancer. Hynes said they studied patients with a good prognosis; most of them were estrogen receptor– or progesterone receptor–positive, had no lymph node involvement, and had low-grade tumors. However, the 7% of patients with an abundance of Memo predicted early metastasis. This study opens up a possible focus on copper chelation therapies, which are currently in phase 2 clinical trials.

Memo Protein Is Prognostic Marker for Poor Outcome in Breast Cancer
Memo Protein Is Prognostic Marker for Poor Outcome in Breast Cancer
(Medical Xpress)-Nancy Hynes and her group at the Friedrich Miescher Institute for Biomedical Research have discovered an important mediator of breast cancer metastasis. The protein called Memo is not only required for cell migration and invasion, it is also an excellent prognostic marker for poor patient outcome and points the way to new therapeutic approaches.
READ FULL ARTICLE From Medical Express

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs